Disruptive Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Disruptive Pharma is a Stockholm-based innovator tackling the pervasive challenge of poor drug solubility in oral medications. Its core asset is the Formulite® platform, a biodegradable mesoporous magnesium carbonate (MMC) material that stabilizes drugs in an amorphous state to dramatically enhance solubility and bioavailability. The company employs a dual strategy, offering formulation services to partners while also developing its own improved versions of established drugs. Having validated its platform in a clinical study, Disruptive Pharma is positioned to create more effective, patient-friendly, and manufacturable oral therapies.

Drug Delivery

Technology Platform

Formulite®: A biodegradable, nanoporous mesoporous magnesium carbonate (MMC) platform that stabilizes drugs in an amorphous state within its pores to enhance solubility, dissolution, and oral bioavailability. It is a dry powder compatible with standard pharmaceutical manufacturing.

Opportunities

The large and growing number of poorly soluble drug candidates in industry pipelines creates a persistent need for effective bioavailability enhancement technologies.

The shift towards patient-centric drug design favors formulations that enable smaller pills, better tolerability, and improved adherence, which Formulite® directly addresses.

Risk Factors

Key risks include technology adoption risk in a conservative industry, execution risk in advancing proprietary product candidates through clinical studies, and financial risk associated with reliance on external funding and partnership milestones.

Intellectual property protection in a competitive field is also a critical challenge.

Competitive Landscape

Disruptive Pharma competes with other drug formulation and bioavailability enhancement companies, including those specializing in amorphous solid dispersions (e.g., using spray drying or hot-melt extrusion), lipid-based systems, and other nanoparticulate technologies. Its differentiation lies in the unique MMC material, which offers a dry, solvent-free, and directly compressible powder process.

More companies in Drug Delivery & Formulation →More companies in Sweden →